Nonalcoholic steatohepatitis

Annals of Internal Medicine

Volumn 126, Issue 2, 1997, Pages 137-145

  Sheth, Sunil G ^a   Gordon, Fredric D ^a   Chopra, Sanjiv ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFIBRATE; LIVER ENZYME; URSODEOXYCHOLIC ACID;

CLINICAL FEATURE; DISEASE COURSE; HEPATITIS; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; LABORATORY DIAGNOSIS; LIVER BIOPSY; LIVER FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; WEIGHT REDUCTION;

EID: 0031038055     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-2-199701150-00008     Document Type: Review

References (85)

1. Ludwig J. Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55: 434-8.
2. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990; 12: 1106-10.
3. Powell EE. Cooksley WG, Hanson R. Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of fortytwo patients for up to 21 years. Hepatology. 1990; 11: 74-80.
4. MacSween RN, Burt AD. Histologie spectrum of alcoholic liver disease. Semin Liver Dis. 1986; 6: 221-32.
5. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet. 1981; 1: 707-11.
6. Gerber MA, Popper H. Relation between central canals and portal tracts in alcoholic hepatitis. A contribution to the pathogenesis of cirrhosis in alcoholics. Hum Pathol. 1972; 3: 199-207.
7. Storey E. Anderson GJ, Mack U. Powell LW, Halliday JW. Desialylated transferrin as a serological marker of chronic excessive alcohol ingestion. Lancet. 1987; 1: 1292-4.
8. Propst A, Propst T, Judmaier G, Vogel W. Prognosis in nonalcoholic steatohepatitis [Letter). Gastroenterology. 1995: 108: 1607.
9. Nonomura A, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; nonalcoholic steatohepatitis and fibrosis. Gastroenterol Jpn. 1992; 27: 521-8.
10. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989; 20: 594-8.
11. Eriksson S, Eriksson KF, Bondesson L Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand. 1986; 220: 83-8. '
12. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr. 1995; 127: 700-4.
13. Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol. 1983; 78: 374-7.
14. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol. 1987; 82: 650-4.
15. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994; 107: 1103-9.
16. Diehl AM. Goodman Z, Ishak KG. Alcohollike disease in nonalcoholics. A clinical and histologie comparison with alcohol-induced liver injury. Gastroenterology. 1988; 95: 1056-62.
17. McFarland RJ, Gazet JC, Pilkington TR. A 13-year review of jejunoileal bypass. Br J Surg. 1985; 72: 81-7.
18. Cello JP, Grendell JH. The liver in systemic conditions. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease. Philadelphia: WB Saunders; 1990: 1428-9.
19. Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, de Moura MC. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sei. 1996; 41: 172-9.
20. Craig RM, Neumann T, Jeejeebhoy KN, Yokoo H. Severe hepatocellular reaction resembling alcoholic hepatitis with cirrhosis after massive small bowel resection and prolonged total parenteral nutrition. Gastroenterology. 1980: 79: 131-7.
21. Ciain DJ, Lefkowitch JH. Fatty liver disease in morbid obesity. Gastroenterol Clin North Am. 1987; 16: 239-52.
22. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986; 8: 283-98.
23. Nazim M, Stamp G, Hodgson HJ. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. Hepatogastroenterology. 1989; 36: 349-51.
24. Hamilton DL. Vest TK. Brown BS, Shah AN, Menguy RB, Chey WY. Liver injury with alcoholiclike hyalin after gastroplasty for morbid obesity. Gastroenterology. 1983; 85: 722-6.
25. Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol. 1992: 87: 775-9.
26. Kimura H, Kako M, Yo K, Oda T. Alcoholic hyalins (Mallory bodies) in a case of Weber-Christian disease: electron microscopic observations of liver involvement. Gastroenterology. 1980: 78: 807-12.
27. Powell EE, Searle J. Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology. 1989; 97: 1022-4.
28. Partin JS, Partin JC, Schubert WK, McAdams AJ. Liver ultrastructure in abetalipoproteinemia: evolution of micronodular cirrhosis. Gastroenterology. 1974; 67: 107-18.
29. Poucell S, Ireton J, Valencia-Mayoral P, Downar E, Larratt L, Patterson J, et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology. 1984; 86(5 Ft 1): 926-36.
30. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis [Letter]. Ann Intern Med. 1995: 123: 236.
31. Pessayre D, Bichara M, Degott C, Polet F, Benhamou JP, Feldmann G. Perhexilene maleate-induced cirrhosis. Gastroenterology. 1979: 76: 170-7.
32. Itoh S, Igarashi M, Tsukada Y, Ichinoe A. Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy. Acta Hepatogastroenterol (Stuttg). 1977: 24: 415-8.
33. Seki K, Minami Y, Nishikawa M, Kawata S, Miyoshi S, Imai Y, et al. "Nonalcoholic steatohepatitis" induced by massive doses of synthetic estro-gen. Gastroenterol Jpn. 1983; 18: 197-203.
34. Dianzani MU. Biochemical aspects of fatty liver. In: Meeks RG, Harrison SD, Bull RJ, eds. Hepatotoxicology. Boca Raton, FL: CRC Pr; 1991: 327-99.
35. Lombard! B. Considerations on the pathogenesis of fatty liver. Lab Invest. 1966; 15(1 Pt 1): 1-20.
36. Cairns SR. Kark AE, Peters TJ. Raised hepatic free fatty acids in a patient with acute fatty liver after gastric surgery for morbid obesity. J Clin Pathol. 1986: 39: 647-9.
37. Mavrelis PG, Ammon HV, Gleysteen JJ, Komorowski RA, Charaf UK. Hepatic free fatty acids in alcoholic liver disease and morbid obesity. Hepatology. 1983: 3: 226-31.
38. Acosta D, Wenzel DG. Injury produced by free fatty acids to lysosomes and mitochondria in cultured heart muscle and endothelial cells. Atherosclerosis. 1974; 20: 417-26.
39. Esterbauer H, Schaur RJ, Zö llner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radie Biol Med. 1991: 11: 81-128.
40. Neuschwander-Tetri BA, Roll FJ. Chemotactic activity for human PMN generated during ethanol metabolism by rat hepatocytes: role of glutathione and glutathione peroxidase. Biochem Biophys Res Commun. 1990; 167: 1170-6.
41. Lee SS, Ho KJ. Cholesterol fatty liver. Morphological changes in the course of its development in rabbits. Arch Pathol. 1975; 99: 301-6.
42. Lee SP. Increased hepatic fibrogenesis in the cholesterol-fed mouse. Clin Sei. 1981: 61: 253-6.
43. Friedman SL Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med. 1993: 328: 1828-35.
44. Wanless IR, Bargman JM, Oreopoulos D, Vas SI. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Mod Pathol. 1989: 2: 69-74.
45. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem. 1980: 49: 395-420.
46. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes. Diabetes. 1986; 35: 990-8.
47. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest. 1984; 74: 1238-46.
48. Moorhouse JA, Steinberg J, Rosen NJ. Sex difference in serum free fatty acid levels in diabetic subjects. J Clin Endocrinol. 1963: 23: 1080-9.
49. Blackard WG, Nelson NC. Portal and peripheral vein immunoreactive insulin concentrations before and after glucose infusion. Diabetes. 1970: 19: 302-6.
50. DeFronzo RA. Insulin secretion, insulin resistance, and obesity. Int J Obes. 1982; 6(Suppl 1): 73-82.
51. McGill DB, Humpherys SR, Baggentoss AH, Dickson ER. Cirrhosis and death after jejunoileal shunt. Gastroenterology. 1972; 63: 872-7.
52. Drenick EJ. Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med. 1970: 282: 829-34.
53. Sherr HP, Nair PP, White JJ. Banwell JG, Lockwood DH. Bile acid metabolism and hepatic disease following small bowel bypass for obesity. Am J Clin Nutr. 1974: 27: 1369-79.
54. Carey JB Jr, Wilson ID, Zaki FG, Hanson RF. The metabolism of bile acids with special reference to liver injury. Medicine (Baltimore). 1966: 45: 461-70.
55. Moxley RT 3d, Pozefsky T, Lockwood DH. Protein nutrition and liver disease after jejunoileal bypass for morbid obesity. N Engl J Med. 1974; 290: 921-6.
56. Marubbio AT Jr, Buchwald H, Schwartz MZ, Varco R. Hepatic lesions of pericellular fibrosis in morbid obesity, and after jejunoileal bypass. Am J Clin Pathol. 1976: 66: 684-91.
57. Baddeley RM. An epilogue to jejunoileal bypass. World J Surg. 1985; 9: 842-9.
58. Carlson LA, Boberg J, Hogstedt B. Some physiological and clinical implications of lipid mobilization from adipose tissue. In: Renold AE, Cahill GF Jr, eds. Handbook of Physiology. Washington, DC: American Physiological Society; 1965: 5: 625-44.
59. Fletcher LM, Kwoh-Gain I, Powell EE, Powell LW, Halliday JW. Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: an aid to diagnosis. Hepatology. 1991: 13: 455-9.
60. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med. 1989; ! 11: 473-8.
61. Rogers DW, Lee CH, Pound DC, Kumar S, Cummings OW, Lumeng L Hepatitis C virus does not cause nonalcoholic steatohepatitis. Dig Dis Sei. 1992; 37: 1644-7.
62. Linnen I. Wages J Jr, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science. 1996; 271: 505-8.
63. Lumeng L New diagnostic markers of alcohol abuse. Hepatology. 1986; 6: 742-5.
64. Stibler H, Borg S. Carbohydrate composition of serum transferrin in alcoholic patients. Alcohol Clin Exp Res. 1986; 10: 61-4.
65. Schellenberg F, Weill J. Serum desialotransferrin in the detection of alcohol abuse. Alcohol Alcohol. 1987; 22(Suppl 1): 624-9.
66. Poupon RE, Schellenberg F, Nalpas B, Weill J. Assessment of the transferrin index in screening heavy drinkers from a general practice. Alcohol Clin Exp Res. 1989; 13: 549-53.
67. Nalpas B, Vassault A, Le Guillou A, Lesgourges B, Ferry N, Lacour B, et al. Serum activity of mitochondrial aspartate aminotransferase: a sensitive marker of alcoholism with or without alcoholic hepatitis. Hepatology. 1984; 4: 893-6.
68. Nalpas B, Vassault A. Charpin S, Lacour B, Berthelot P. Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: diagnostic value and interpretation in a liver unit. Hepatology. 1986; 6: 608-14.
69. Panteghini M, Malchiodi A, Calarco M, Bonora R. Clinical and diagnostic significance of aspartate aminotransferase isoenzymes in sera of patients with liver diseases. J Clin Chem Clin Biochem. 1984; 22: 153-8.
70. Itoh S, Matsuo S, Ichinoe A, Yamaba Y, Miyazawa M. Nonalcoholic steatohepatitis and cirrhosis with Mallory's hyalin with ultrastructural study of one case. Dig Dis Sei. 1982; 27: 341-6.
71. Nasrallah SM, Wills CE Jr, Galambos JT. Hepatic morphology in obesity. Dig Dis Sei. 1981: 26: 325-7.
72. Andersen T, Gluud C. Liver morphology in morbid obesity: a literature study. Int J Obes. 1984; 8: 97-106.
73. Lee RG. Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler. Hepatology. 1995; 21: 1742-3.
74. Falchuk KR, Fiske SC, Haggitt RC, Federman M. Trey C Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. Gastroenterology. 1980; 78: 535-41.
75. Galambos JT. Natural history of alcoholic hepatitis. 3. Histological changes. Gastroenterology. 1972; 63: 1026-35.
76. Marbet UA, Blanchi L, Meury U, Stalder GA. Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease. J Hepatol. 1987; 4: 364-72.
77. Haines NW, Baker AL, Boyer JL. Glagov S, Schneir H, Jaspan J, et al. Prognostic indicators of hepatic injury following jejunoileal bypass performed for refractory obesity: a prospective study. Hepatology. 1981: 1: 161-7.
78. Vyberg M. Ravn V, Andersen B. Patterns of progression in liver injury following jejunoileal bypass for morbid obesity. Liver. 1987; 7: 271-6.
79. Capron JP, Delamarre J, Dupas JL. Braillon A, Degott C, Quenum C Fasting in obesity: another cause of liver injury with alcoholic hyaline? Dig Dis Sei. 1982; 27: 265-8.
80. Keeffe EB, Adesman PW, Stenzel P, Palmer RM. Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. Dig Dis Sei. 1987; 32: 441-5.
81. Lonardo A, Bellini M, Tondelli E, Frazzoni M, Grisendi A, Pulvirenti M, et al. Nonalcoholic steatohepatitis'and the "bright liver syndrome": should a recently expanded clinical entity be further expanded? [Letter] Am J Gastroenterol. 1995: 90: 2072-4.
82. Rosental P, Biava C, Spencer H, Zimmerman HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis. 1967; 12: 198-208.
83. Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol. 1995: 20: 127-30.
84. Hofmann AF. Bile acid hepatotoxicity and the rationale of UDCA therapy in chronic cholestatic liver disease: some hypotheses. In: Paumgartner G, Steihl A, Barbara L, Roda E, eds. Strategies for the Treatment of Hepatobiliary Diseases. Boston: Kluwer Academic; 1990: 13-34.
85. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996: 23: 1464-7.